New Result Shows High Therapeutic Benefits For Boehringer Ingelheim’ Mirapexin/Sifrol

Boehringer Ingelheim presented new data at the Movement Disorder Society’s 13th International Congress of Parkinson’s Disease and Movement Disorders (MDS). The new results confirms high therapeutic benefit of Mirapexin/Sifrol (pramipexole) once-daily, extended release formulation.

The study supports data from a previous trial that demonstrated the efficacy, safety and tolerability of the once daily formulation in the treatment of early PD at 18 weeks, and non-inferiority between pramipexole extended release and pramipexole immediate release at 33 weeks.

The randomised, placebo-controlled trial assessed the efficacy and safety of a once-daily, extended release formulation of pramipexole (administered as adjunctive therapy in advanced PD) compared to its immediate formulation when administered under the same therapeutic conditions. Both the primary and the key secondary endpoints were met in the study as measured by the change from baseline in UPDRS II+III and percentage of off-time during waking hours.